ClinicalTrials.gg
Active, not recruitingNCT04494425DB-06Updated Mar 4, 2026Results posted

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

A Phase 3 interventional study of Trastuzumab deruxtecan and Capecitabine in Advanced or Metastatic Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 293 sites in 28 countries. Open to participants aged 18 Years to 105 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
866
Allocation
Randomized
Ages
18 Years to 105 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
4th of 58
866 · median 139
Started
2020
with 8 others
Phase 3
12 of 58
3 open now
Primary completion
2024-03
later than 2 of 44 live
Registered
12th of 58
by date
Lead sponsor
9 of 58
AstraZeneca

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 9 that started in 2020, is one of 12 in phase 3, reaches primary completion later than 2 of the 44 other live ones, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 105 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Read the detailed description

Eligible patients will be those patients who have had disease progression on at least 2 previous lines of endocrine therapies given for the treatment of metastatic disease or disease progression within 6 months of starting first line treatment for metastatic disease with an endocrine therapy combined with a CDK4/6 inhibitor. All patients must have historically confirmed HR positive (either estrogen receptor and/or progesterone receptor positive), HER2-low (defined as IHC2+/ISH- and IHC 1+) or HER2 IHC >0 \<1+ expression, as determined by central laboratory testing results, advanced or metastatic breast cancer.

The study aims to evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy. This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the cancer affects patients' quality of life.

03

Conditions studied

  • Advanced or Metastatic Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • HR positive
  • HER2-Low
  • HER2-Negative
  • Trastuzumab Deruxtecan (T-DXd; DS-8201a)
  • Anti-HER2-Antibody Drug Conjugate (ADC)
  • DESTINY-Breast06
04

Who can participate

Ages eligible
18 Years to 105 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must be ≥18 years of age
  • documented breast cancer that:

    1. is advanced or
    2. has a history of -low or negative expression by local test, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested) or HER2 IHC 0 (ISH- or untested)
    3. has HER2-low or HER2 IHC >0 \<1+ expression as determined by the central laboratory result established on a tissue sample taken in the metastatic setting
    4. was never previously HER2-positive
    5. is documented HR+ disease in the metastatic setting.
  • No prior chemotherapy for advanced or metastatic breast cancer.
  • Has adequate tumor samples for assessment of HER2 status
  • Must have either:

    1. disease progression within 6 months of starting metastatic treatment with an endocrine therapy combined with a CDK4/6 inhibitor or
    2. disease progression on at least 2 previous lines of endocrine therapy with or without a targeted therapy in the metastatic setting. Of note with regards to the ≥2 lines of previous ET requirement: disease recurrence while on the first 24 months of starting adjuvant ET, will be considered a line of therapy; these patients will only require 1 line of ET in the metastatic setting.
  • Has protocol-defined adequate organ and bone marrow function

Key Exclusion Criteria:

  • Ineligible for all options in the investigator's choice chemotherapy arm
  • Lung-specific intercurrent illnesses
  • Uncontrolled or significant cardiovascular disease or infection
  • Prior documented interstitial lung disease (ILD)/ pneumonitis that required , current ILD/ pneumonitis, or suspected ILD/ pneumonitis that cannot be ruled out by imaging at screening.
  • Patients with spinal cord compression or clinically active central nervous system metastases
  • Prior randomization or treatment in a previous trastuzumab deruxtecan study regardless of treatment arm assignment
  • Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study during the follow up period of a prior interventional study (prescreening for this study while a patient is on treatment in another clinical study is acceptable)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
866 participants (actual)

Study arms

  • Experimental
    Trastuzumab deruxtecan

    Trastuzumab deruxtecan (T-DXd; DS-8201a) arm

    Drug: Trastuzumab deruxtecan

  • Active comparator
    Standard of Care

    Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm

    Drug: Capecitabine · Drug: Paclitaxel · Drug: Nab-Paclitaxel

Interventions

  • Trastuzumab deruxtecan by intravenous infusion

    Also known as: DS-8201a; T-DXd

  • Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.

  • Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.

  • Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population

    PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by BICR was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of target lesions (TLs), taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 millimeter (mm) from nadir. Median PFS was calculated using Kaplan-Meier method and its confidence interval (CI) using Brookmeyer-Crowley method.

    Time frame: Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

Secondary outcomes

  1. Overall Survival (OS) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population

    OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

    Time frame: From date of randomization until death due to any cause, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  2. Progression-Free Survival Assessed by Blinded Independent Central Review in the Intent-to-Treat, Human Epidermal Growth Factor Receptor 2 Immunohistochemistry (IHC) >0 <1+ and Human Epidermal Growth Factor Receptor 2-low Population

    PFS per RECIST 1.1 assessed by BICR was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median PFS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

    Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  3. Overall Survival (OS) in the Intent-to-Treat Population

    OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

    Time frame: From date of randomization until death due to any cause, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  4. Progression-Free Survival Assessed by Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population

    PFS per RECIST 1.1 assessed by Investigator was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median PFS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

    Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  5. Objective Response Rate (ORR) Assessed by Blinded Independent Central Review and Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population

    ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR). CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

    Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  6. Duration of Response (DOR) Assessed by Blinded Independent Central Review and Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population

    DOR per RECIST v1.1 was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median DOR was calculated using Kaplan-Meier method.

    Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  7. Objective Response Rate Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat and Human Epidermal Growth Factor Receptor 2 Immunohistochemistry >0 <1+ Population

    ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of CR or PR. CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

    Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  8. Duration of Response Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat Population

    DOR per RECIST v1.1 was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median DOR was calculated using Kaplan-Meier method.

    Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  9. Time From Randomization to Second Progression or Death (PFS2) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population

    PFS2 was defined as time from randomization to second progression (the earliest of the progression event subsequent to first subsequent therapy) or death; second progression was defined according to local standard clinical practice and might involve any of the following: objective radiological imaging, symptomatic progression, or death. Median PFS2 was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

    Time frame: Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  10. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. A serious adverse event (SAE) was an AE occurring during any study phase, that fulfilled 1 or more of following criteria: resulted in death, was immediately life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was congenital abnormality or birth defect, and was an important medical event that jeopardized participant or required medical treatment to prevent 1 of outcomes listed above. TEAE was any AE that occurred, having been absent before the first dose of study drug, or had worsened in severity or seriousness after initiation of the study drug until the 40-day (+7 days) safety follow-up visit.

    Time frame: From first dose of study drug (Day 1) up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  11. Serum Concentration of Trastuzumab Deruxtecan (T-DXd), Total Anti-Human Epidermal Growth Factor Receptor 2 Antibody and MAAA-1181a

    Blood samples were collected at indicated time points to determine the concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a in serum.

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 4, 6 and 8; 15 minutes post-dose on Day 1 of Cycles 1, 2 and 4; and 5 hours post-dose on Day 1 of Cycle 1 (each cycle is 21 days)

  12. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scale Score at Week 91

    EORTC QLQ-C30 is a 30-item self-administered questionnaire grouped into 5 multi-item functional scales(physical,role,emotional,cognitive and social),3 multiitem symptom scales(fatigue,pain and nausea/vomiting),2-item global QoL scale,5 single items assessing additional symptoms reported by cancer participants(dyspnea,loss of appetite,insomnia,constipation and diarrhea). All but 2 questions have 4-point scales:1:not at all,2:a little,3:quite a bit,4:very much.2 questions concerning global health status and QoL have 7-point scales with responses ranging from 1:very poor to 7:excellent;higher score:better level of functioning/greater degree of symptoms.For each of 15 scales,final scores were averaged from scores of component items,transformed,range: 0 to 100;higher scores:better functioning,better health related (HR)QoL,or greater level of symptoms(higher scores:opposite interpretations for functioning/QoL and symptoms/problems).Baseline:last observed measurement prior to randomization.

    Time frame: Baseline (Day 1) and Week 91

  13. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Breast Module 45 (BR45) Scale Score at Week 58

    EORTC QLQ-BR45 is an updated version of the BR23. Self-administered instrument includes original 23-items yielding 5 multi-item scores (body image, sexual functioning, arm symptoms, breast symptoms, and systemic therapy side effects). Additional 22 items yield 4 additional multi-item scales (breast satisfaction, endocrine therapy symptoms, skin mucosis symptoms, and endocrine sexual symptoms). Single items assess sexual enjoyment, future perspective and being upset by hair loss. Items are scored on a 4-point verbal rating scale: 1: not at all, 2: a little, 3: quite a bit, and 4: very much; higher score: better level of functioning or greater degree of symptoms. Scores of these scales were averaged from scores of component items, transformed, and ranged from 0 to 100; higher scores for functioning scales or items indicate better functioning, whereas higher scores for symptom scales or items represent a higher level of symptoms. Baseline:last observed measurement prior to randomization.

    Time frame: Baseline (Day 1) and Week 58

  14. Time to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Scale Score

    Time to deterioration was defined as the time from randomization until the date of the first clinically meaningful deterioration that was confirmed at next available assessment, at least 14 days apart, regardless of whether the participant withdrew from study treatment or receives another anti-cancer therapy prior to deterioration.

    Time frame: From randomization until date of first symptom deterioration that is confirmed, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  15. Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab Deruxtecan

    Blood samples were collected at indicated timepoints to determine ADA. Treatment-induced ADA was defined as ADA positive post-baseline and not detected at baseline (negative or missing). Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following drug administration.

    Time frame: From Day 1 up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

  16. Time to First Subsequent Treatment or Death (TFST) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population

    TFST was defined as time from randomization to the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment or death due to any cause.

    Time frame: From Day 1 up to 64 months

  17. Time to Second Subsequent Treatment or Death (TSST) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population

    TSST was defined as time from randomization to the start date of the second subsequent anti-cancer therapy after discontinuation of randomized treatment or death due to any cause.

    Time frame: From Day 1 up to 64 months

07

Results

Posted Apr 2, 2025

Participant flow

This Phase III, multi-center, open-label study was conducted in participants with human epidermal growth factor receptor 2 (HER2)-low, hormone receptor-positive (HR+) breast cancer at 273 sites in 28 countries. Results are presented based on primary completion date (PCD) of up to 18 March 2024.

Participant flow — Overall Study
MilestoneT-DXdChemotherapy
Started436430
Randomized and received treatment434417
Completed00
Not completed436430
Withdrew: Death160166
Withdrew: Withdrawal by subject1040
Withdrew: Other11
Withdrew: Ongoing at the time of pcd265223

Outcome measures

PrimaryProgression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population

PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by BICR was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of target lesions (TLs), taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 millimeter (mm) from nadir. Median PFS was calculated using Kaplan-Meier method and its confidence interval (CI) using Brookmeyer-Crowley method.

Time frame:
Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population
monthsT-DXdChemotherapy
Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population13.2 (11.4 to 15.2)8.1 (7.0 to 9.0)
Statistical analysis
  • T-DXd vs Chemotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.62 · 95% CI 0.52 to 0.75HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for prior cyclin-dependent kinase (CDK)4/6 inhibitor use (yes versus no) and HER2 IHC expression (IHC 1+ versus IHC 2+/ISH-) and ties handled by Efron approach.
SecondaryOverall Survival (OS) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population

OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

Time frame:
From date of randomization until death due to any cause, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Overall Survival (OS) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population
monthsT-DXdChemotherapy
Overall Survival (OS) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population28.9 (25.7 to 33.7)27.1 (23.5 to 29.9)
SecondaryProgression-Free Survival Assessed by Blinded Independent Central Review in the Intent-to-Treat, Human Epidermal Growth Factor Receptor 2 Immunohistochemistry (IHC) >0 <1+ and Human Epidermal Growth Factor Receptor 2-low Population

PFS per RECIST 1.1 assessed by BICR was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median PFS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

Time frame:
Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Progression-Free Survival Assessed by Blinded Independent Central Review in the Intent-to-Treat, Human Epidermal Growth Factor Receptor 2 Immunohistochemistry (IHC) >0 <1+ and Human Epidermal Growth Factor Receptor 2-low Population
monthsT-DXdChemotherapy
ITT Population13.2 (12.0 to 15.2)8.1 (7.0 to 9.0)
HER2 IHC >0 <1+ Population13.2 (9.8 to 17.3)8.3 (5.8 to 15.2)
HER2-low Population12.8 (11.1 to 13.2)7.0 (6.4 to 7.5)
SecondaryOverall Survival (OS) in the Intent-to-Treat Population

OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy. Median OS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

Time frame:
From date of randomization until death due to any cause, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Overall Survival (OS) in the Intent-to-Treat Population
monthsT-DXdChemotherapy
Overall Survival (OS) in the Intent-to-Treat Population28.9 (26.4 to 32.7)27.4 (23.9 to 29.9)
SecondaryProgression-Free Survival Assessed by Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population

PFS per RECIST 1.1 assessed by Investigator was defined as the time from the date of randomization until the date of PD, as defined or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median PFS was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

Time frame:
Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Progression-Free Survival Assessed by Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population
monthsT-DXdChemotherapy
Progression-Free Survival Assessed by Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population12.8 (11.1 to 13.2)7.0 (6.4 to 7.5)
SecondaryObjective Response Rate (ORR) Assessed by Blinded Independent Central Review and Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population

ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR). CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

Time frame:
Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review and Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population
percentage of participantsT-DXdChemotherapy
BICR Assessment60.437.9
Investigator Assessment60.440.4
SecondaryDuration of Response (DOR) Assessed by Blinded Independent Central Review and Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population

DOR per RECIST v1.1 was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median DOR was calculated using Kaplan-Meier method.

Time frame:
Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Duration of Response (DOR) Assessed by Blinded Independent Central Review and Investigator in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low Population
monthsT-DXdChemotherapy
BICR Assessment13.6 (6.2 to 24.9)7.3 (4.2 to 15.2)
Investigator Assessment12.0 (6.6 to 20.0)6.9 (3.1 to 11.1)
SecondaryObjective Response Rate Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat and Human Epidermal Growth Factor Receptor 2 Immunohistochemistry >0 <1+ Population

ORR per RECIST 1.1 assessed by BICR and Investigator was defined as the percentage of participants with at least 1 visit response of CR or PR. CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \<10 mm. PR was defined as at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

Time frame:
Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Number · percentage of participants
Objective Response Rate Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat and Human Epidermal Growth Factor Receptor 2 Immunohistochemistry >0 <1+ Population
percentage of participantsT-DXdChemotherapy
BICR Assessment: ITT Population61.536.7
Investigator Assessment: ITT Population61.538.8
BICR Assessment: HER2 IHC >0 <1+ Population67.131.6
Investigator Assessment: HER2 IHC >0 <1+ Population65.831.6
SecondaryDuration of Response Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat Population

DOR per RECIST v1.1 was defined as the time from the date of first documented response until date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir), this included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm from nadir. Median DOR was calculated using Kaplan-Meier method.

Time frame:
Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Duration of Response Assessed by Blinded Independent Central Review and Investigator in the Intent-to-Treat Population
monthsT-DXdChemotherapy
BICR Assessment13.7 (6.5 to 24.9)7.3 (4.2 to 15.9)
Investigator Assessment12.1 (6.8 to 20.0)6.9 (3.0 to 12.5)
SecondaryTime From Randomization to Second Progression or Death (PFS2) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population

PFS2 was defined as time from randomization to second progression (the earliest of the progression event subsequent to first subsequent therapy) or death; second progression was defined according to local standard clinical practice and might involve any of the following: objective radiological imaging, symptomatic progression, or death. Median PFS2 was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.

Time frame:
Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Time From Randomization to Second Progression or Death (PFS2) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population
monthsT-DXdChemotherapy
HER2-low Population20.0 (18.9 to 23.8)14.5 (12.9 to 15.5)
ITT Population20.3 (18.9 to 23.8)14.7 (13.5 to 15.9)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. A serious adverse event (SAE) was an AE occurring during any study phase, that fulfilled 1 or more of following criteria: resulted in death, was immediately life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was congenital abnormality or birth defect, and was an important medical event that jeopardized participant or required medical treatment to prevent 1 of outcomes listed above. TEAE was any AE that occurred, having been absent before the first dose of study drug, or had worsened in severity or seriousness after initiation of the study drug until the 40-day (+7 days) safety follow-up visit.

Time frame:
From first dose of study drug (Day 1) up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsT-DXdChemotherapy
TEAEs429397
TESAEs8867
SecondarySerum Concentration of Trastuzumab Deruxtecan (T-DXd), Total Anti-Human Epidermal Growth Factor Receptor 2 Antibody and MAAA-1181a

Blood samples were collected at indicated time points to determine the concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a in serum.

Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 4, 6 and 8; 15 minutes post-dose on Day 1 of Cycles 1, 2 and 4; and 5 hours post-dose on Day 1 of Cycle 1 (each cycle is 21 days)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Serum Concentration of Trastuzumab Deruxtecan (T-DXd), Total Anti-Human Epidermal Growth Factor Receptor 2 Antibody and MAAA-1181a
micrograms per milliliter (mcg/mL)T-DXd
T-DXd: Day 1: pre-dose, Cycle 1NA ± NA
T-DXd: Day 1: pre-dose, Cycle 24.35225 ± 8.958729
T-DXd: Day 1: pre-dose, Cycle 48.21037 ± 9.464435
T-DXd: Day 1: pre-dose, Cycle 68.65950 ± 4.753592
T-DXd: Day 1: pre-dose, Cycle 811.31496 ± 22.894112
T-DXd: Day 1: 15 minutes post-dose, Cycle 1135.90160 ± 102.989325
T-DXd: Day 1: 15 minutes post-dose, Cycle 2136.74872 ± 108.860006
T-DXd: Day 1: 15 minutes post-dose, Cycle 4124.60481 ± 39.812165
T-DXd: Day 1: 5 hours post-dose, Cycle 1123.82288 ± 30.513998
Total anti-HER2 antibody: Day 1: pre-dose, Cycle 1NA ± NA
Total anti-HER2 antibody: Day 1: pre-dose, Cycle 25.75841 ± 11.351915
Total anti-HER2 antibody: Day 1: pre-dose, Cycle 412.00513 ± 11.087226
Total anti-HER2 antibody: Day 1: pre-dose, Cycle 613.97891 ± 8.720790
Total anti-HER2 antibody: Day 1: pre-dose, Cycle 817.47641 ± 27.144299
Total anti-HER2 antibody: Day 1: 15 minutes post-dose, Cycle 1141.27586 ± 114.137606
Total anti-HER2 antibody: Day 1: 15 minutes post-dose, Cycle 2146.17993 ± 134.780719
Total anti-HER2 antibody: Day 1: 15 minutes post-dose, Cycle 4131.06830 ± 44.228380
Total anti-HER2 antibody: Day 1: 5 hours post-dose, Cycle 1119.64619 ± 26.591288
MAAA-1181a: Day 1: pre-dose, Cycle 1NA ± NA
MAAA-1181a: Day 1: pre-dose, Cycle 20.261850 ± 0.2096642
MAAA-1181a: Day 1: pre-dose, Cycle 40.401004 ± 0.2825761
MAAA-1181a: Day 1: pre-dose, Cycle 60.446237 ± 0.2957478
MAAA-1181a: Day 1: pre-dose, Cycle 80.432894 ± 0.2819292
MAAA-1181a: Day 1: 15 minutes post-dose, Cycle 16.014366 ± 3.1859583
MAAA-1181a: Day 1: 15 minutes post-dose, Cycle 22.985606 ± 1.9276120
MAAA-1181a: Day 1: 15 minutes post-dose, Cycle 42.411409 ± 1.5862547
MAAA-1181a: Day 1: 5 hours post-dose, Cycle 113.917874 ± 6.5178612
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scale Score at Week 91

EORTC QLQ-C30 is a 30-item self-administered questionnaire grouped into 5 multi-item functional scales(physical,role,emotional,cognitive and social),3 multiitem symptom scales(fatigue,pain and nausea/vomiting),2-item global QoL scale,5 single items assessing additional symptoms reported by cancer participants(dyspnea,loss of appetite,insomnia,constipation and diarrhea). All but 2 questions have 4-point scales:1:not at all,2:a little,3:quite a bit,4:very much.2 questions concerning global health status and QoL have 7-point scales with responses ranging from 1:very poor to 7:excellent;higher score:better level of functioning/greater degree of symptoms.For each of 15 scales,final scores were averaged from scores of component items,transformed,range: 0 to 100;higher scores:better functioning,better health related (HR)QoL,or greater level of symptoms(higher scores:opposite interpretations for functioning/QoL and symptoms/problems).Baseline:last observed measurement prior to randomization.

Time frame:
Baseline (Day 1) and Week 91
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scale Score at Week 91
score on a scaleT-DXdChemotherapy
Physical Functioning-7.88 ± 17.389-4.85 ± 13.520
Role Functioning-14.77 ± 21.631-12.12 ± 26.318
Emotional Functioning-6.06 ± 25.4401.52 ± 22.218
Cognitive Functioning-8.71 ± 22.872-6.82 ± 19.009
Social Functioning-10.98 ± 23.000-7.58 ± 21.656
Fatigue11.87 ± 24.3678.59 ± 18.444
Pain-1.89 ± 21.025-0.76 ± 24.922
Nausea/Vomiting9.85 ± 19.128-0.76 ± 12.037
Global Health Status/QoL-7.77 ± 23.529-10.61 ± 22.150
Dyspnea6.06 ± 23.0411.52 ± 21.767
Loss of Appetite12.88 ± 30.6826.06 ± 19.616
Insomnia6.06 ± 26.190-15.15 ± 24.618
Constipation11.36 ± 30.4521.52 ± 12.503
Diarrhea6.82 ± 19.79213.64 ± 28.469
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Breast Module 45 (BR45) Scale Score at Week 58

EORTC QLQ-BR45 is an updated version of the BR23. Self-administered instrument includes original 23-items yielding 5 multi-item scores (body image, sexual functioning, arm symptoms, breast symptoms, and systemic therapy side effects). Additional 22 items yield 4 additional multi-item scales (breast satisfaction, endocrine therapy symptoms, skin mucosis symptoms, and endocrine sexual symptoms). Single items assess sexual enjoyment, future perspective and being upset by hair loss. Items are scored on a 4-point verbal rating scale: 1: not at all, 2: a little, 3: quite a bit, and 4: very much; higher score: better level of functioning or greater degree of symptoms. Scores of these scales were averaged from scores of component items, transformed, and ranged from 0 to 100; higher scores for functioning scales or items indicate better functioning, whereas higher scores for symptom scales or items represent a higher level of symptoms. Baseline:last observed measurement prior to randomization.

Time frame:
Baseline (Day 1) and Week 58
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Breast Module 45 (BR45) Scale Score at Week 58
score on a scaleT-DXdChemotherapy
Body Image-3.12 ± 23.585-5.42 ± 22.349
Sexual Functioning-2.96 ± 12.7081.46 ± 14.081
Arm Symptoms-5.30 ± 20.496-3.06 ± 18.540
Breast Symptoms-2.41 ± 17.132-2.19 ± 12.631
Systemic Therapy Side Effects5.65 ± 15.5363.99 ± 15.536
Breast Satisfaction2.65 ± 30.9820.85 ± 31.428
Endocrine Therapy Symptoms-0.14 ± 11.3160.17 ± 12.458
Skin Mucosis Symptoms4.67 ± 14.72112.22 ± 18.232
Endocrine Sexual Symptoms3.66 ± 20.8312.00 ± 15.969
Sexual Enjoyment-3.03 ± 17.9790.00 ± 20.101
Future Perspective8.72 ± 32.16111.25 ± 29.022
Being Upset By Hair Loss2.47 ± 34.5000.00 ± 40.825
SecondaryTime to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Scale Score

Time to deterioration was defined as the time from randomization until the date of the first clinically meaningful deterioration that was confirmed at next available assessment, at least 14 days apart, regardless of whether the participant withdrew from study treatment or receives another anti-cancer therapy prior to deterioration.

Time frame:
From randomization until date of first symptom deterioration that is confirmed, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Median · months
Time to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Scale Score
monthsT-DXdChemotherapy
Physical Functioning18.0 (15.9 to NA)9.9 (6.9 to 15.2)
Role Functioning10.3 (6.9 to 14.6)5.5 (4.1 to 6.9)
Emotional Functioning28.2 (18.6 to NA)17.3 (12.4 to NA)
Cognitive Functioning11.8 (8.3 to 16.6)9.9 (7.8 to 13.8)
Social Functioning11.7 (7.6 to 16.3)7.7 (6.2 to 10.4)
Fatigue4.3 (3.4 to 7.7)2.9 (2.2 to 4.2)
Pain22.0 (17.2 to NA)6.3 (4.8 to 9.6)
Nausea/Vomiting3.5 (2.8 to 5.6)13.8 (7.7 to 21.5)
Global Health Status/QoL11.3 (8.3 to 14.7)10.5 (7.7 to 13.3)
Dyspnea20.0 (19.3 to NA)20.8 (13.1 to NA)
Loss of Appetite8.3 (5.0 to 11.7)13.8 (9.6 to 16.1)
InsomniaNA (17.3 to NA)15.2 (12.4 to NA)
Constipation9.2 (5.5 to 12.5)22.0 (15.9 to NA)
Diarrhea29.0 (17.2 to NA)16.5 (13.9 to 23.4)
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab Deruxtecan

Blood samples were collected at indicated timepoints to determine ADA. Treatment-induced ADA was defined as ADA positive post-baseline and not detected at baseline (negative or missing). Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following drug administration.

Time frame:
From Day 1 up to PCD of 18 March 2024 (maximum of approximately 43.85 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab Deruxtecan
ParticipantsT-DXd
Treatment-induced ADA22
Treatment-boosted ADA0
SecondaryTime to First Subsequent Treatment or Death (TFST) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population

TFST was defined as time from randomization to the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment or death due to any cause.

Time frame:
From Day 1 up to 64 months

Results for this outcome have not been posted.

SecondaryTime to Second Subsequent Treatment or Death (TSST) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population

TSST was defined as time from randomization to the start date of the second subsequent anti-cancer therapy after discontinuation of randomized treatment or death due to any cause.

Time frame:
From Day 1 up to 64 months

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study drug (Day 1) up to PCD of 18 March 2024 (maximum of approximately 43.85 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-DXd161/436 (36.9%)88/434 (20.3%)427/434 (98.4%)
Chemotherapy174/430 (40.5%)67/417 (16.1%)383/417 (91.8%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventT-DXdChemotherapy
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders8/4340/417
PneumonitisRespiratory, thoracic and mediastinal disorders8/4340/417
COVID-19Infections and infestations7/4341/417
CellulitisInfections and infestations1/4345/417
Pleural effusionRespiratory, thoracic and mediastinal disorders0/4345/417
Febrile neutropeniaBlood and lymphatic system disorders5/4342/417
HypokalaemiaMetabolism and nutrition disorders5/4341/417
ColitisGastrointestinal disorders0/4343/417
DiarrhoeaGastrointestinal disorders1/4343/417
CholangitisHepatobiliary disorders0/4343/417
Most frequent other events
Showing 10 of 56
Most frequent other events
EventT-DXdChemotherapy
NauseaGastrointestinal disorders301/434126/417
AlopeciaSkin and subcutaneous tissue disorders210/43487/417
AnaemiaBlood and lymphatic system disorders157/434106/417
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders4/434145/417
DiarrhoeaGastrointestinal disorders148/434112/417
VomitingGastrointestinal disorders145/43448/417
ConstipationGastrointestinal disorders136/43460/417
FatigueGeneral disorders117/43483/417
Aspartate aminotransferase increasedInvestigations117/43444/417
Decreased appetiteMetabolism and nutrition disorders112/43447/417

Baseline characteristics

The Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)T-DXdChemotherapyTotal
Mean58.2 ± 11.4658.2 ± 10.9258.2 ± 11.19
Sex: Female, Male
Sex: Female, Male(Participants)T-DXdChemotherapyTotal
Female436429865
Male011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)T-DXdChemotherapyTotal
Black or African American437
American Indian or Alaska Native101
Asian154151305
White231230461
Other71219
Not reported393473
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)T-DXdChemotherapyTotal
Hispanic or Latino283260
Not Hispanic or Latino397387784
Missing111122
08

Study locations

293 sites
  • Research Site
    Scottsdale, Arizona 85259, United States
  • Research Site
    Springdale, Arkansas 72762, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Lakewood, Colorado 80228, United States
  • Research Site
    Washington D.C., District of Columbia 20016, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Summit, New Jersey 07901, United States
  • Research Site
    Westbury, New York 11590, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Madison, Wisconsin 53792-5666, United States
  • Research Site
    Buenos Aires, C1125ABD, Argentina
  • Research Site
    CABA, 1414, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    CABA, C1019ABS, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1280, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    Rosario, S2002KDS, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Birtinya, 4575, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Charleroi, 6060, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30110-022, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20560-120, Brazil
  • Research Site
    São Paulo, 04038-034, Brazil
  • Research Site
    São Paulo, 1323001, Brazil
  • Research Site
    Sorocaba, 18030-510, Brazil
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Toronto, CA M5G 2M9, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Baoding, 071000, China
  • Research Site
    Beijing, 100006, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Dalian, 116001, China
  • Research Site
    Foshan, 528000, China
  • Research Site
    Fuzhou, 350011, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Jinan, 250001, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shanghai, 200032, China

Showing the first 100 of 293 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Levy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. PubMed 39282896 ↗
  • Tarantino P, Tolaney SM, Curigliano G. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann Oncol. 2023 Oct;34(10):949-950. doi: 10.1016/j.annonc.2023.07.003. Epub 2023 Jul 26. No abstract available. PubMed 37499870 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Mar 2024, 43 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 43 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 31, 2020
StartActual
Jul 24, 2020
Primary completionActual
Mar 18, 2024
CompletionEst.
Jun 19, 2026
Results first posted
Apr 2, 2025
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04494425
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 31, 2020
Start date
Jul 24, 2020
Primary completion
Mar 18, 2024
Completion
Jun 19, 2026 (estimated)
Results posted
Apr 2, 2025
Last update
Mar 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion